company background image
VIVO logo

Meridian Bioscience NasdaqGS:VIVO Voorraadrapport

Laatste prijs

US$33.97

Marktkapitalisatie

US$1.5b

7D

0.06%

1Y

54.3%

Bijgewerkt

01 Feb, 2023

Gegevens

Financiële gegevens bedrijf +

Meridian Bioscience, Inc.

NasdaqGS:VIVO Voorraadrapport

Marktkapitalisatie: US$1.5b

VIVO Overzicht aandelen

Meridian Bioscience, Inc., a life science company, develops, manufactures, distributes, and sells diagnostic test kits primarily for gastrointestinal and respiratory infectious diseases, and elevated blood lead levels worldwide. Meer informatie

Meridian Bioscience, Inc. Concurrenten

Prijsgeschiedenis en prestaties

Overzicht van alle hoogtepunten, veranderingen en prijsdalingen voor Meridian Bioscience
Historische aandelenkoersen
Huidige aandelenkoersUS$33.97
52 Week HoogtepuntUS$34.38
52 Week LaagUS$21.09
Bèta0.23
11 maand verandering2.29%
3 maanden verandering6.02%
1 Jaar Verandering54.34%
33 jaar verandering295.23%
5 jaar verandering128.75%
Verandering sinds IPO6,030.20%

Recent nieuws en updates

Recent updates

Meridian Bioscience Non-GAAP EPS of $0.16 misses by $0.01, revenue of $67.8M beats by $1M

Aug 05

Meridian Bioscience: High-Probability Merger Arbitrage

Jul 26

Meridian Bioscience downgraded at William Blair on $1.53B acquisition

Jul 07

Meridian Bioscience (NASDAQ:VIVO) Has A Pretty Healthy Balance Sheet

Jun 27
Meridian Bioscience (NASDAQ:VIVO) Has A Pretty Healthy Balance Sheet

Meridian Bioscience: Correctly Valued

Jun 26

Many Would Be Envious Of Meridian Bioscience's (NASDAQ:VIVO) Excellent Returns On Capital

Jun 09
Many Would Be Envious Of Meridian Bioscience's (NASDAQ:VIVO) Excellent Returns On Capital

Meridian Bioscience: Deceptively Priced

Mar 14

Meridian Bioscience (NASDAQ:VIVO) Looks To Prolong Its Impressive Returns

Feb 03
Meridian Bioscience (NASDAQ:VIVO) Looks To Prolong Its Impressive Returns

These 4 Measures Indicate That Meridian Bioscience (NASDAQ:VIVO) Is Using Debt Safely

Jul 19
These 4 Measures Indicate That Meridian Bioscience (NASDAQ:VIVO) Is Using Debt Safely

If The COVID-19 Delta Variant Spreads This Fall, Meridian Is Still A Buy

Jul 08

Meridian Bioscience (NASDAQ:VIVO) Might Become A Compounding Machine

May 10
Meridian Bioscience (NASDAQ:VIVO) Might Become A Compounding Machine

Meridian Bioscience, Inc. 2021 Q2 - Results - Earnings Call Presentation

May 08

Meridian Bioscience (NASDAQ:VIVO) Seems To Use Debt Rather Sparingly

Mar 31
Meridian Bioscience (NASDAQ:VIVO) Seems To Use Debt Rather Sparingly

Have Insiders Been Buying Meridian Bioscience, Inc. (NASDAQ:VIVO) Shares?

Mar 11
Have Insiders Been Buying Meridian Bioscience, Inc. (NASDAQ:VIVO) Shares?

Investors Who Bought Meridian Bioscience (NASDAQ:VIVO) Shares A Year Ago Are Now Up 185%

Feb 24
Investors Who Bought Meridian Bioscience (NASDAQ:VIVO) Shares A Year Ago Are Now Up 185%

Need To Know: Analysts Are Much More Bullish On Meridian Bioscience, Inc. (NASDAQ:VIVO) Revenues

Feb 09
Need To Know: Analysts Are Much More Bullish On Meridian Bioscience, Inc. (NASDAQ:VIVO) Revenues

Meridian expands production capacity for COVID-19 tests with NIH funding

Feb 03

Should We Be Excited About The Trends Of Returns At Meridian Bioscience (NASDAQ:VIVO)?

Jan 27
Should We Be Excited About The Trends Of Returns At Meridian Bioscience (NASDAQ:VIVO)?

Rendement voor aandeelhouders

VIVOUS Medical EquipmentUS Markt
7D0.06%1.7%0.3%
1Y54.3%21.4%31.1%

Rendement versus industrie: VIVO overtrof de US Medical Equipment industrie, die het afgelopen jaar een rendement 21.4 % opleverde.

Rendement versus markt: VIVO overtrof de US markt, die het afgelopen jaar een rendement opleverde van 31.1 %.

Prijsvolatiliteit

Is VIVO's price volatile compared to industry and market?
VIVO volatility
VIVO Average Weekly Movement2.3%
Medical Equipment Industry Average Movement8.0%
Market Average Movement6.2%
10% most volatile stocks in US Market15.8%
10% least volatile stocks in US Market3.1%

Stabiele aandelenkoers: VIVO heeft de afgelopen 3 maanden geen significante prijsvolatiliteit gekend.

Volatiliteit in de loop van de tijd: De wekelijkse volatiliteit ( 2% ) van VIVO is het afgelopen jaar stabiel geweest.

Over het bedrijf

OpgerichtWerknemersCEOWebsite
1976704Jack Kennywww.meridianbioscience.com

Meridian Bioscience, Inc. Samenvatting

Hoe verhouden de winst en inkomsten van Meridian Bioscience zich tot de beurswaarde?
VIVO fundamentele statistieken
MarktkapitalisatieUS$1.49b
Inkomsten(TTM)US$42.46m
Inkomsten(TTM)US$333.02m

35.2x

Koers/Winstverhouding

4.5x

P/S-verhouding

Inkomsten en omzet

Belangrijkste winstgevendheidsstatistieken uit het laatste winstverslag (TTM)
VIVO resultatenrekening (TTM)
InkomstenUS$333.02m
Kosten van inkomstenUS$144.66m
BrutowinstUS$188.36m
Overige uitgavenUS$145.90m
InkomstenUS$42.46m

Laatst gerapporteerde inkomsten

Sep 30, 2022

Volgende inkomensdatum

n.v.t.

Winst per aandeel (EPS)0.96
Brutomarge56.56%
Nettowinstmarge12.75%
Schuld/Eigen Vermogen Verhouding6.8%

Hoe presteerde VIVO op de lange termijn?

Bekijk historische prestaties en vergelijking